Skip to main content
. 2022 Apr 29;33(11):2018–2034. doi: 10.1021/acs.bioconjchem.2c00030

Figure 4.

Figure 4

The DS-Cav1-I53–50 nanoparticle immunogen. (A) A vaccine against respiratory syncytial virus (RSV) was engineered by outwardly displaying a trimeric RSV antigen (DS-Cav1) on the trimeric subunit of a computationally designed nanoparticle (I53–50). (B) Negative stain electron microscopy of I53–50 and DS-Cav1-I53–50 nanoparticles. Left: representative micrographs. Right: averages of nanoparticle micrographs. (C–D) Antibody binding titers ofDS-Cav-1-specific antibodies (C) or serum neutralizing antibodies (D) from mice immunized with bare nanoparticle (I53–50), free immunogen (DS-Cav1), or nanoparticle immunogens (DS-Cav1-I53–50) at valencies of 33%, 67%, or 100%. Each point represents and individual animal, geometric means are represented by horizontal lines and indicated at the bottom of the plots, and statistical significance is indicated: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See original publication for more details. Reprinted with permission.(98)